Seamus Fernandez
Stock Analyst at Guggenheim
(4.91)
# 46
Out of 5,112 analysts
117
Total ratings
67.47%
Success rate
69.31%
Average return
Main Sectors:
Stocks Rated by Seamus Fernandez
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TENX Tenax Therapeutics | Maintains: Buy | $14 → $25 | $12.49 | +100.16% | 3 | Dec 17, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $120 → $140 | $111.00 | +26.13% | 3 | Dec 17, 2025 | |
| BMY Bristol-Myers Squibb Company | Upgrades: Buy | $62 | $53.69 | +15.48% | 13 | Dec 12, 2025 | |
| SNY Sanofi | Downgrades: Neutral | n/a | $47.96 | - | 1 | Dec 9, 2025 | |
| IVA Inventiva | Maintains: Buy | $13 → $11 | $4.58 | +140.17% | 1 | Nov 18, 2025 | |
| CDTX Cidara Therapeutics | Downgrades: Neutral | n/a | $220.03 | - | 6 | Nov 18, 2025 | |
| MBX MBX Biosciences | Maintains: Buy | $84 → $77 | $28.24 | +172.66% | 4 | Nov 10, 2025 | |
| ARCT Arcturus Therapeutics Holdings | Downgrades: Neutral | n/a | $6.72 | - | 4 | Oct 23, 2025 | |
| LLY Eli Lilly and Company | Reiterates: Buy | $948 | $1,068.36 | -11.27% | 20 | Oct 16, 2025 | |
| AMLX Amylyx Pharmaceuticals | Maintains: Buy | $17 → $25 | $12.10 | +106.61% | 2 | Sep 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $92 → $90 | $61.15 | +47.18% | 2 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $116 | $75.50 | +53.64% | 8 | Jul 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | n/a | $28.77 | - | 3 | Apr 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $160 | $43.07 | +271.49% | 4 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | n/a | $36.62 | - | 2 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $130 → $122 | $100.46 | +21.44% | 14 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $48.60 | - | 2 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $5.16 | - | 3 | Apr 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $48.15 | - | 2 | May 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $135.56 | - | 6 | Feb 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $7.88 | - | 1 | Feb 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $56 → $54 | $3.08 | +1,653.25% | 1 | Mar 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $60 → $45 | $25.58 | +75.92% | 3 | Mar 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $36 → $38 | $90.47 | -58.00% | 6 | Feb 6, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $35 → $38 | $25.07 | +51.61% | 3 | Jan 31, 2018 |
Tenax Therapeutics
Dec 17, 2025
Maintains: Buy
Price Target: $14 → $25
Current: $12.49
Upside: +100.16%
Rhythm Pharmaceuticals
Dec 17, 2025
Maintains: Buy
Price Target: $120 → $140
Current: $111.00
Upside: +26.13%
Bristol-Myers Squibb Company
Dec 12, 2025
Upgrades: Buy
Price Target: $62
Current: $53.69
Upside: +15.48%
Sanofi
Dec 9, 2025
Downgrades: Neutral
Price Target: n/a
Current: $47.96
Upside: -
Inventiva
Nov 18, 2025
Maintains: Buy
Price Target: $13 → $11
Current: $4.58
Upside: +140.17%
Cidara Therapeutics
Nov 18, 2025
Downgrades: Neutral
Price Target: n/a
Current: $220.03
Upside: -
MBX Biosciences
Nov 10, 2025
Maintains: Buy
Price Target: $84 → $77
Current: $28.24
Upside: +172.66%
Arcturus Therapeutics Holdings
Oct 23, 2025
Downgrades: Neutral
Price Target: n/a
Current: $6.72
Upside: -
Eli Lilly and Company
Oct 16, 2025
Reiterates: Buy
Price Target: $948
Current: $1,068.36
Upside: -11.27%
Amylyx Pharmaceuticals
Sep 15, 2025
Maintains: Buy
Price Target: $17 → $25
Current: $12.10
Upside: +106.61%
Aug 7, 2025
Maintains: Buy
Price Target: $92 → $90
Current: $61.15
Upside: +47.18%
Jul 2, 2025
Reiterates: Buy
Price Target: $116
Current: $75.50
Upside: +53.64%
Apr 3, 2025
Reiterates: Buy
Price Target: n/a
Current: $28.77
Upside: -
Mar 12, 2025
Reiterates: Buy
Price Target: $160
Current: $43.07
Upside: +271.49%
Feb 24, 2025
Reiterates: Buy
Price Target: n/a
Current: $36.62
Upside: -
Jan 17, 2025
Maintains: Buy
Price Target: $130 → $122
Current: $100.46
Upside: +21.44%
Oct 31, 2024
Downgrades: Neutral
Price Target: n/a
Current: $48.60
Upside: -
Apr 29, 2024
Downgrades: Neutral
Price Target: n/a
Current: $5.16
Upside: -
May 31, 2022
Upgrades: Buy
Price Target: n/a
Current: $48.15
Upside: -
Feb 25, 2020
Downgrades: Neutral
Price Target: n/a
Current: $135.56
Upside: -
Feb 3, 2020
Downgrades: Neutral
Price Target: n/a
Current: $7.88
Upside: -
Mar 13, 2018
Maintains: Outperform
Price Target: $56 → $54
Current: $3.08
Upside: +1,653.25%
Mar 8, 2018
Maintains: Market Perform
Price Target: $60 → $45
Current: $25.58
Upside: +75.92%
Feb 6, 2018
Maintains: Market Perform
Price Target: $36 → $38
Current: $90.47
Upside: -58.00%
Jan 31, 2018
Maintains: Market Perform
Price Target: $35 → $38
Current: $25.07
Upside: +51.61%